Literature DB >> 9779385

Value of noninvasive studies in community-acquired pneumonia.

J F Plouffe1, C McNally, T M File.   

Abstract

Noninvasive diagnostic studies, i.e., sputum gram stain, sputum culture, blood culture and antigen detection assays will assist the clinician in the selection of initial antimicrobial therapy in some patients. These tests may be even more valuable in adjusting treatment regimens to prevent the use of broad spectrum antimicrobial agents as routine therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9779385     DOI: 10.1016/s0891-5520(05)70205-1

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  5 in total

1.  Targets for antibiotic and healthcare resource stewardship in inpatient community-acquired pneumonia: a comparison of management practices with National Guideline Recommendations.

Authors:  T C Jenkins; S A Stella; L Cervantes; B C Knepper; A L Sabel; C S Price; L Shockley; M E Hanley; P S Mehler; W J Burman
Journal:  Infection       Date:  2012-11-17       Impact factor: 3.553

2.  Procalcitonin versus C-reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care.

Authors:  Anette Holm; Svend S Pedersen; Joergen Nexoe; Niels Obel; Lars P Nielsen; Ole Koldkjaer; Court Pedersen
Journal:  Br J Gen Pract       Date:  2007-07       Impact factor: 5.386

Review 3.  Diagnostic test for etiologic agents of community-acquired pneumonia.

Authors:  John G Bartlett
Journal:  Infect Dis Clin North Am       Date:  2004-12       Impact factor: 5.982

Review 4.  Diagnosis and management of respiratory tract infections for the primary care physician.

Authors:  S C Wei; J Norwood
Journal:  Obstet Gynecol Clin North Am       Date:  2001-06       Impact factor: 2.844

Review 5.  Laboratory diagnosis of community-acquired lower respiratory tract infection.

Authors:  M A Saubolle; P P McKellar
Journal:  Infect Dis Clin North Am       Date:  2001-12       Impact factor: 5.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.